liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Osteoporosis: the emperor has no clothes
University of Helsinki, Finland; University of Helsinki, Finland.
Uppsala University, Sweden.
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Orthopaedics in Linköping.
UKK Institute Health Promot Research, Finland.
2015 (English)In: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 277, no 6, 662-673 p.Article in journal (Refereed) Published
Abstract [en]

Current prevention strategies for low-trauma fractures amongst older persons depend on the notions that fractures are mainly caused by osteoporosis (pathophysiology), that patients at high risk can be identified (screening) and that the risk is amenable to bone-targeted pharmacotherapy (treatment). However, all these three notions can be disputed. PathophysiologyMost fracture patients have fallen, but actually do not have osteoporosis. A high likelihood of falling, in turn, is attributable to an ageing-related decline in physical functioning and general frailty. ScreeningCurrently available fracture risk prediction strategies including bone densitometry and multifactorial prediction tools are unable to identify a large proportion of patients who will sustain a fracture, whereas many of those with a high fracture risk score will not sustain a fracture. TreatmentThe evidence for the viability of bone-targeted pharmacotherapy in preventing hip fracture and other clinical fragility fractures is mainly limited to women aged 65-80years with osteoporosis, whereas the proof of hip fracture-preventing efficacy in women over 80years of age and in men at all ages is meagre or absent. Further, the antihip fracture efficacy shown in clinical trials is absent in real-life studies. Many drugs for the treatment of osteoporosis have also been associated with increased risks of serious adverse events. There are also considerable uncertainties related to the efficacy of drug therapy in preventing clinical vertebral fractures, whereas the efficacy for preventing other fractures (relative risk reductions of 20-25%) remains moderate, particularly in terms of the low absolute risk reduction in fractures with this treatment.

Place, publisher, year, edition, pages
Wiley: 12 months , 2015. Vol. 277, no 6, 662-673 p.
Keyword [en]
cost-effectiveness; osteoporosis; prediction; screening; treatment
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-119579DOI: 10.1111/joim.12366ISI: 000355000400004PubMedID: 25809279OAI: diva2:825199

Funding Agencies|Eli Lilly Corp

Available from: 2015-06-23 Created: 2015-06-22 Last updated: 2015-06-24

Open Access in DiVA

fulltext(1150 kB)96 downloads
File information
File name FULLTEXT01.pdfFile size 1150 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Aspenberg, Per
By organisation
Division of Clinical SciencesFaculty of Medicine and Health SciencesDepartment of Orthopaedics in Linköping
In the same journal
Journal of Internal Medicine
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 96 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 148 hits
ReferencesLink to record
Permanent link

Direct link